Center for Liver Diseases
The UPMC Center for Liver Diseases (CLD) offers patients a full range of liver disease treatments, including cutting edge therapies for:
|Viral hepatitis (B and C)
Fatty liver disease
Primary biliary cirrhosis
Primary sclerosing cholangitis
Alpha 1 antitrypsin deficiency
Hepatocellular carcinoma (HCC)
The CLD’s hepatologists are nationally recognized for their expertise in liver diseases. The Center provides convenient access to comprehensive liver disease care by coordinating patient care with a number of subspecialists, including experts in hepatobiliary and transplant surgery, therapeutic endoscopy, pathology and oncology.
The primary patient care clinic is located at the Frank Sarris Outpatient Clinic on the 7th floor of UPMC Montefiore. Satellite CLD clinic sites include: Magee Womens Hospital of UPMC; Digestive Disorders Center at UPMC Presbyterian; UPMC Passavant; UPMC Horizon in Greenville, PA; UPMC McKeesport; and locations in Monroeville, West Mifflin and Butler.
Thanks to the national reputation of our liver specialists and UPMC’s vast network, the CLD participates in some of the largest clinical trials in the country. The Center’s primary research themes and major ongoing trials include:
- Therapies for hepatitis C and B in transplant and non-transplant patients
- Novel approaches to the evaluation, management and follow up of patients with fatty liver disease
- Treatment of Alpha-One Antitrypsin Deficiency
- Relationship between physical deconditioning and hospitalization for patients listed for liver transplantation: Assessing activity levels by use of a wearable activity monitor for patients with chronic liver disease listed on the transplant wait list
- Phase 2 randomized study evaluating safety and tolerability of investigational study medications for patients with NASH for patients with stage F2 or F3 fibrosis
- Phase 2, randomized, double-blind, placebo-controlled, dose-finding, clinical trial evaluating the efficacy and safety of an investigational study medication in subjects with primary sclerosing cholangitis
- Treatment of HCV Genotypes 1-6, compensated cirrhotics for both naïve, current and past treatment failures with multiple sponsors
- Treatment of non-cirrhotic NASH patients – randomized placebo controlled trial
- Thrombocytopenia treatment for PLT <50,000 prior to planned invasive procedure
The Center for Liver Diseases team offers significant expertise in diagnosing, treating, and curing liver diseases.
Margaret Andrzejewski, PA-C